Fig. 8

Tumor targetability of HACB NPs. A In vivo fluorescence imaging of HeLa tumor-bearing mice at 1, 2, 6, 12 and 24 h after intravenous injection of (I) free DiR, (II) HACB/DiR NPs with pre-injection of free HA and (III) HACB/DiR NPs. B Ex vivo fluorescence imaging of the tumor and normal tissues harvested from the euthanized HeLa tumor-bearing mice at 24 h post-injection. C Region-of-interest analysis of fluorescent signals from the tumors and normal tissues. Data are shown as mean ± S. D. (n = 3), *p < 0.05, **p < 0.01 and ***p < 0.001